INTRODUCTION
Chronic myeloid leukemia (CML) accounts for about 15% of all leukemia in the developing world [1] , and though it is not restricted to any age, CML is predominantly an adult disease, accounting for 20% of all leukemia in adults, with an estimated incidence of 1.6 per 100,000 in U.S alone, and 5430 diagnosed new cases in 2012 [2] . CML is a particularly aggressive and lethal myeloproliferative pathology, originating from the hematopoietic cancer stem cells (hCSCs) due to Bcl-Abl tyrosine kinase -mediated transformation of primitive hematopoietic cells and formation of the Philadelphia (Ph) chromosome. The role of hCSCs in tumor progression, metastasis, chemoresistance and recurrence in CML is well documented; however, targeting these hCSCs as an effective anti-CML strategy is relatively less explored [3] .
Despite our current limited knowledge of the specific oncogenic events that initiate and/or sustain CML, CML remains a paradigm for hematopoietic stem cell (hSC)-derived malignancy, and the implication of hCSCs in the initiation, drug-resistance, distant metastases and recurrence of CML is increasingly becoming a focus of anticancer research [4, 5] .
The small molecule inhibitor of Bcr-Abl kinase, Imatinib mesylate (IM), with demonstrated induction of complete cytogenetic and hematologic response in most chronic phase CML patients is the current standard of care for Ph + CML [6] , however, unfortunately, IM does not provide definitive cure to CML patients because of the development of resistance to IM by the Bcr-Abl fusion gene, as well as the primary insensitivity of hCSCs to IM [7] . This is also true of the other Bcr-Abl kinase inhibitors such as nilotinib and dasatinib, which have been shown to be ineffective in CML harboring BCR-ABL-T315I mutation, thus, rendering the therapeutic promise of IM and these other Bcr-Abl kinase inhibitors elusive in CML. In addition, STAT5 has been shown to contribute to two hallmarks for tumor initiation and malignant progression [8] . First, STAT5 can override the STAT3-mediated cell death program in the normal mammary epithelium. In addition, elevated STAT5 expression has been detected in subset of primary human breast cancers [9] and the constitutive STAT5 activation in luminal epithelial cells and multipotent progenitors is sufficient to initiate breast tumorigenesis [10] . More importantly, the activation of STAT5 through JAK2 has been demonstrated to be required for the initiation of mammary tumors in vivo [11] . It has been well established that downstream of BcrAbl, STAT5 functions to prevent apoptosis in CML cells. Together, targeting Brc-Abl/STAT5 axis may represent a more effective approach for CML interventions.
Hematopoietic CSCs, harbor stem cell-like properties, namely, high expression of stemness markers, self-renewal, initiation and maintenance of cancer, and resistance to anticancer treatment, thus constitute potential molecular targets for screening novel anti-CML drugs. Previously, Bamodu et al. demonstrated that Ovatodiolide (Ova) sensitizes triple negative breast cancer cells to doxorubicin and eliminates their CSC-like phenotype [12] , and this was corroborated by Lu et al. who demonstrated that the inhibition of breast cancer stem/progenitor cells by Ova was through a SMURF2-mediated downregulation of Hsp27 [13] . Ova is a bioactive macrocyclic diterpenoid compound purified from the traditional Chinese herbal medicine Anisomeles indica (L.) Kuntze, with documented antiinflammatory, antiangiogenesis, antibacterial, antiviral, antioxidant, and anticancer activities [14, 15] , however, nothing is known about the therapeutic effect of Ova in hematologic cancers, more so, regarding their ability to target and/or inhibit the CD34
− hCSCs, therefore, in this study, we investigated the microRNA (miRNA)-mediated epigenetically therapeutic effect of Ova in the CML hCSCs and its underlying molecular mechanism.
miRNAs are small non-coding RNAs that are actively involved in the modulation of transcription factors and gene expression by binding to the 3′untranslated regions (3′UTRs) of the target messenger RNA (mRNA) to repress them [16] . miRNA expression has also been shown to change during the differentiation of certain hematopoietic stem cell (hSC) lineages [17] . In fact, animal models with silenced or ectopic expression of certain miRNAs have been used to demonstrate that miRNAs play very important role in the erythropoietic, granulopoietic, and monocytopoietic process, as well as in the development of T-lymphocytes [18, 19] . This is further corroborated by the implication of altered miRNA expression in hematologic cancers, howbeit more in mice models [20] .
In this study, we report the hsa-miR-155-mediated Ova suppression of CD34+/CD38 − CML cell viability and hCSC-like phenotype, including their associated pluripotency and survival signaling, through the dysregulation the PI3K/AKT/mTOR signaling pathway. 
RESULTS

CD34
CD38
− cells showed enhanced expression of the stemness markers Oct4, Sox2 and CD133 on the protein and mRNA levels ( Figure 1C and 1D Since more than 90% of CML cases harbor the Bcr-Abl (t 9;22) chromosomal translocation and have been shown to respond to some degree to IM, a selective inhibitor of the Bcr-Abl tyrosine kinase, to understand how the cytogenetic classification of CML cells may affect their response to chemotherapy, we examined the effect of IM on the unsorted and sorted K562 cells. Using the cytotoxicity assay, we demonstrated that while IM (Figure 2A − hCSC-like cells to form tumorspheres ( Figure 3A) . Then using the apoptosis assay, we demonstrated that while 0.1 μM IM induced apoptosis in 13%, when combined with 2.5 μM Ova, apoptotic cells increased to 44%, a 3.4-fold increase compared to IM alone. In same vein, apoptosis was induced in 33% or 58% of cells treated with IM alone or in combination with Ova, respectively, showing a 25% increase in the apoptotic cell population ( Figure 3B and Supplementary Figure 1) . This data was corroborated by the up-regulation of the pro-apoptosis marker, Bax, in the CD34
− hCSClike cells treated with 2.5 μM Ova alone or in combination with 0.1 or 1 μM IM, compared with IM alone or untreated control groups, as well as a down-regulation in the antiapoptosis marker, Bcl-2 when treated with Ova alone or in combination with IM, compared with the IM alone or untreated control groups ( Figure 3C ). In addition, we demonstrated that this Ova-mediated increased induction of apoptosis and Bax/Bcl-2 ratio was correlated with dose-dependent significant reduction in the expression levels of Bcr-Abl, p-PI3K, p-Akt, p-mTOR and CD44 ( Figure 3D and Supplementary Figure 2) . It is notable that this inhibitory effect of Ova alone or in combination with IM in CD34 + hCSCs is similar to that elicited by silencing the gene that encodes for the p110a catalytic sub-unit of PI3K, PIK3CA, using a short interfering RNA (siPIK3CA) (Supplementary Figure 3) . Similarly, Ova treatment was upregulates hsa-miR-155 expression, while concurrently dysregulating the PI3K/mTOR signaling axis in the KU812 cells (Supplementary Figure 4) . These data indicate that Ova by deregulating the PI3K/AKT/mTOR signaling pathway, increases the Bax/Bcl-2 ratio, induce cell death signals and lead to increased apoptosis of the CD34
− hCSC-like cells.
Ovatodiolide suppress CD34 + /CD38 − hCSCs via epigenetic modulation of the PI3K/mTOR signaling axis Based on the demonstrated critical role of miRNAs in erythropoiesis, granulopoiesis, monocytopoiesis, T-lymphocyte development, and the implication of altered miRNA expression in hematologic cancers [20] , we analyzed the miRNA expression profile in CML hCSCs and unsorted K562 parental cells using RT-PCR. Our RT-PCR results showed that miR-155 and miR-34a were significantly down-regulated while miR-409-3p and miR-21 were conversely up-regulated in the CD34 + /CD38
− hCSCs compared to the unsorted K562 parental cells ( Figure 4A) . Further, we demonstrated that treatment with 2.5 μM Ova could reverse this expression trend by significantly increasing the expression of miR-155 and miR-34a while inhibiting the expression of miR-409-3p and miR-21 in the Ova-treated CD34
− hCSCs compared to their untreated CD34
− or unsorted K562 parental counterparts ( Figure 4B ). By using TargetScan [22], we carried out genomic mapping of miR-155, and established that the 5′UTR of miR-155 binds to the position 106-112 of the 3′UTR of PIK3CA ( Figure 5C, upper panel) , which is the gene that encodes for the p110a catalytic sub-unit of PI3K to induce transcriptional repression of PI3K and by inference deregulate the PI3K/AKT/mTOR, as shown in the RT-PCR data where treatment with miR-155 mimic down-regulated the mRNA expression of Stat5, NF-kB, mTOR, and PIK3CA, while miR-155 inhibitor up-regulated their expression ( Figure 4C, lower panel) . This data was corroborated at the protein level by western blot analysis data ( Figure 4D ) and data from the RT-PCR analyses showing that treatment with 2.5μM and 5 μM Ova, increased the expression of hsa-miR-155 in CD34+ K562 cells, with corresponding upregulation in the expressions of PIK3CA, mTOR, and STAT5 ( Figure 4E ). The molecular docking to demonstrate direct interaction between chain B8 of hsa-miR-155 and chain A of PI3KCA with a docking score of -250.59, and a ligand RMSD of 178.10 Å ( Figure  4F ). These findings indicate that Ova effectively suppress
− hCSCs via a miR155-mediated epigenetic modulation of the PI3K/mTOR signaling axis.
DISCUSSION
CML hCSCs constitute a small population of CML cells which play a critical role in the initiation and maintenance of CML [3, 4, 5] . In the present study, we identified that CD34
− CML cells harboring the Bcr-Abl fusion gene, were enriched with Oct4, Sox2 and CD133 (Figure 1 ). The identification of the over-expression of these CSC-specific markers in the CD34
− CML cells, has been associated with tumor aggressiveness, metastasis, resistance to treatment and tumor recurrence [1, 3] , thus defining an enhanced hCSC-like phenotype. This is consistent with the seminal findings of initial studies by Bonnet and Dick's team on leukemia wherein flow cytometry-based sorting was used to isolate a subpopulation of leukemic cells with the CD34
− cell surface phenotype identified in bone marrow samples of acute 
CD38
− cells resulted in the development of leukemia in the mice models, thus, this small subset of leukemia cells with inherently greater stem cell self-renewal potential, compared to other leukemia or normal adult bone marrow cells, was then referred to as CSCs [23, 24] .
Thus we worked on the premise that targeting these aggressive self-renewing Bcr-Abl + CD34 + /CD38 − hCSCs could be an effective strategy for the eradication of CML. Our study showed that though IM is a selective inhibitor of the t(9;22) chromosomal translocation-based BCR-ABL tyrosine kinase, unfortunately, its therapeutic effect was limited in scope and efficacy, especially against the CD34 + /CD38 − hCSCs (Figure 2) . Interestingly, this is not an isolated finding, as it is corroborated by another study which identified that despite the significant cytogenetic and hematological response observed in CML patients treated with IM, the presence of minimal residual disease detectable by sensitive quantitative -PCR, was inevitable, thus demonstrating that quiescent CML hCSCs were insensitive to STI571 or IM by using a FACS -based assay [25] . In the light of this observed innate reduced sensitivity of the CD34
− hCSCs to the standard of care, IM, in the present study, we employed a new approach to eradicate these primitive quiescent Bcr-Abl + CD38
− cells. We found that Ova, a bioactive macrocyclic diterpenoid isolate of Anisomeles indica (L.) Kuntze, with demonstrated anti-CSCs activity in solid tumor [12, 13] exhibited significantly inhibited the viability, Bcr-Abl signaling, and hCSC-like phenotype of these CD34 + /CD38
− cells, and most importantly, we showed that Ova enhances the toxicity of IM across all CML cell populations, CD3 4 
+/CD38
− inclusive (Figures 2 and 3 ). This anti-hCSCs activity of Ova in CML cells is consistent with previous results obtained in solid tumors, such as in the triple negative breast cancer (TNBC), where exposure to Ova increased the sensitivity of doxorubicin -resistant TNBC cells to doxorubicin, and induced the loss of CSC-like phenotype in the TNBC cells, as demonstrated by significant dissolution and necrosis of formed mammospheres [12] , as well as in colon cancer, where treatment with Ova suppressed the expression of YAP1, inhibited M2 macrophage polarization, and prevented the generation of CSC-like colonospheres [26] . Our findings with Ova have clinical implications as these identified IMinsensitive hCSCs also exist in vivo as evidenced by the persistence of about 20% Bcr-Abl + CD34 + and long-term culture-initiating cells in patients who achieved a complete cytogenetic response [27] , low incidence of remission among IM-treated CML patients, and tumor recurrence when IM therapy is halted, often to blast crisis [28] .
The therapeutic activity of Ova in the BcrAbl + CD34 + /CD38 − hCSCs was also shown to inhibit the phosphorylation of Stat5, up-regulate MDR and deregulate the PI3K/AKT/mTOR signaling pathway. During progression of CML, several signaling pathways become activated in cancer cells, however, many converge into principal downstream signaling networks, such as, the PI3K and STAT pathways which are very critical in the evolution of drug-resistant CML. Deregulating the activation of their components, such as Akt or Stat5 has been associated with curative efficacy in CML, suggesting that they are probable drivers of oncogenesis in the drug-resistant Bcr-Abl + CD34
+ /CD38 − hCSCs [29] . This agrees with the demonstrated involvement of the BcrAbl tyrosine kinase with activation of several signaling pathways, such as the mitogen-activated protein kinase (MAPK), c-jun N-terminal kinase (JNK/SAPK), Ras small GTPase, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), signal transducers and activator of transcription (STAT), and phosphoinositide 3-kinases (PI3K), thus, promoting cell viability, proliferation and reduced apoptosis [30] . Currently, we are investigating Ova's in vivo function using xenograft mouse model. Our preliminary data indicated that Ova treatment significantly suppressed tumorigenesis initiated by inoculating CD34+/ CD38 − cells (data not shown). Further investigation was set to determine the potential synergistic effect of using Ova and Imatinib in vivo. This information will provide insights for designing future clinical trials for the treatment of drug-resistant CML patients.
Finally, we identified miRNAs that are deferentially expressed in CD34
− and unsorted K562 cells, namely, miR-409-3p and miR-21 which are up-regulated and miR-34a and miR-155 which are down-regulated; in addition noting that Ova reverses this expression profile, such that after Ova treatment, expression levels of miR-409-3p and miR-21 are markedly reduced, while that of miR-34a and miR-155 are significantly enhanced, with associated down-regulation of Stat5, NF-kB, m-TOR and PIK3CA (Figure 4 ). These findings are in agreement with those published earlier demonstrating that miR-31, miR-155, and miR-564 are down-regulated in CML cells [31] , creating a therapeutic window wherein the molecular or therapeutic (as in our case using Ova) enhancement of miR-155 expression and/or activity could play a critical role in reversing the oncogenic effect of the activated Stat5 and the PI3K/AKT/ mTOR signaling pathway.
In conclusion, our studies identify a novel miR-155-dependent mechanism of regulating the aberrant oncogenic activity of the Stat5 and PI3K/AKT/mTOR signaling in the persistent IM-resistant the Bcr-Abl + CML K562 cells by performing the fluorescence-activated cell-sorting (FACS) assay as previously described [33] , and defined the quadrants by fluorescein isothiocyanate (FITC) and PE-labeled isotype controls. Further, we obtained defined numbers of CML cells for reverse transcription polymerase chain reaction (RT-PCR) analyses following a previously described protocol [34] .
MATERIALS AND METHODS
Drugs and chemicals
Western blot analysis
By using the 10% SDS-PAGE gel, 15 μg total protein samples was fractionated by electrophoresis and transferred to a Polyvinylidene fluoride (PVDF) membrane in the Bio-Rad Mini-Protein electro-transfer system (Bio-Rad Laboratories, Inc, CA, USA). Incubation of the membranes in 5% skimmed milk -Tris-buffered saline with Tween 20 (TBST) for 1 h to block non- (1 : 1000, Santa Cruz), and β-actin (1 : 500, Santa Cruz). The membranes were then washed and incubated in appropriate horseradish peroxidise (HRP)-conjugated secondary antibodies for 1 h at room temperature, then washed with PBS 3 times. Protein bands were then detected in the enhanced chemiluminescence (ECL) detection system (Thermo Fisher Scientific Inc, Waltham, MA, USA) and quantification was done using the ImageJ software.
Culturing of cells into tumorspheres
After sorting the cells, the unsorted, CD34 + /CD38 -, and CD34 + /CD38 + cells were seeded at 1000 cells per well in 6-well non-adherent plates (Corning Inc., Corning, NY) in DMEM/F12 medium supplemented with bFGF (20 ng/mL, Invitrogen, Carlsbad, CA), B27 supplement (Invitrogen, Carlsbad, CA), and EGF (20 ng/mL, Millipore, Bedford, MA). Cells were cultured for 10-12 days, and the formed tumorspheres were counted using inverted phase contrast microscopy.
Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from the CML cells using Trizol reagent according to the manufacturer's instructions, and reverse-transcribed using the first-strand cDNA Synthesis Kit (Fermentas UAB, Vilnius, Lithuania) following the manufacturers' instructions. RT-PCR was carried out with 50 μL of reaction-mix containing 1 μg cDNA template, 1 μM specific oligonucleotide primers, and 25 μL Taq mixtures containing 0.5 unit of Taq DNA polymerase. We separated PCR products by electrophoresis in 2% agarose gel. 
Sulforhodamine B cell viability assay
/CD38
+ cells were fixed with 10% Trichloroacetic acid (TCA), washed with ddH 2 O, and stained with 0.4% SRB (w/v) in 1% acetic acid. The unbound dye was removed by carefully washing with 1% acetic acid 4 times and the plates were air-dried.
Bound SRB dye was then dissolved in 10 μM Trizma, and the absorbance was read at 570 nm wavelength in a microplate reader.
Statistical analysis
Each experiment was performed at least 3 times in duplicates. All data represent means ± SD. Comparison between two groups was estimated using the 2-sided Student's t-test, while the one-way analysis of variance (ANOVA) was used for comparison between 3 or more groups. P-value < 0.05 was considered statistically significant.
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